Merck and ICx cancer theranostic pact:
This article was originally published in Clinica
Executive Summary
Merck & Co has teamed up with ICx Technologies and Fred Hutchinson Cancer Research Center of Seattle to develop theranostic blood tests for cancer. The tests will look for nucleic acids in the blood that can help determine if certain cancer therapies are appropriate for a patient. Arlington, Virginia-based ICx will incorporate its data-rich molecular diagnosis technology - previously developed for security applications - into the tests. The research will be conducted at the company's La Jolla, California-based Biosystems unit.